1283114

Solaris Pharma Corp — FEI 3012158090

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
September 18, 2025
Fiscal Year
2025
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Somerset, NJ (United States)

Additional Details

Postmarket Adverse Drug Experience (PADE)

Citations

IDCFRDescription
683221 CFR 314.80(c)(2)Late submission of annual safety reports